Advertisement


David Raben, MD, on NSCLC: Results From the PACIFIC Trial

2018 ASTRO Annual Meeting

Advertisement

David Raben, MD, of the University of Colorado, discusses overall survival with durvalumab vs placebo after chemoradiotherapy in stage III non–small cell lung cancer (Abstract LBA10).



Related Videos

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer: Prospective Trials Update

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses a session on data from several long-term studies on localized disease, including optimal sequencing of radiation an...

Prostate Cancer

Howard M. Sandler, MD, on Localized Prostate Cancer: Radiation Therapy Guidelines

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, summarizes a session he moderated that included discussion of an ASTRO, ASCO, and AUA guideline; indications and dose fractionation; treatment...

Issues in Oncology

Vinai Gondi, MD, on Treating Brain Metastases, Preserving Cognitive Function

Vinai Gondi, MD, of Northwestern Medicine, discusses the early results of a phase III NRG Oncology trial that suggests a practice change in treating brain metastases: avoiding the ...

Lung Cancer

Daniel R. Gomez, MD, on NSCLC: Findings From a Phase II Treatment Trial

Daniel R. Gomez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final results of a phase II study on local consolidative therapy, which improved overall su...

Head and Neck Cancer

Bhisham Chera, MD, on Oropharyngeal Cancer: Expert Perspective on Surveillance

Bhisham Chera, MD, of the University of North Carolina, discusses using human papillomavirus found in plasma circulating tumor DNA to monitor cancer recurrence in HPV-associa...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.